AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30428902 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group, n = 100)
Number of subjects: 200
Study 30428902 — intervention group
Group type: EXPERIMENTAL
Intervention: Online eHealth platform (online group, n = 50)
Number of subjects: 200
Study 30428902 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless monitoring devices (device group, n = 50)
Number of subjects: 200
Study 27834984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxycodone 0.1 mg kg⁻¹
Number of subjects: 50
Study 27834984 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.1 mL kg⁻¹
Number of subjects: 50
Study 24747504 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine hydrochloride (Memary) at a dose of 20 mg/day
Number of subjects: 702
Study 22797514 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydrin-P (tropicamide and phenylephrine)
Number of subjects: 29
Study 22797514 — intervention group
Group type: COMPARATOR
Intervention: Unpreserved saline (placebo)
Number of subjects: 29
Study 22797514 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Mydrin-P and saline
Number of subjects: 29
Study 20970380 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate with whole brain radiotherapy (n=154)
Number of subjects: 551
Study 20970380 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate without whole brain radiotherapy (n=164)
Number of subjects: 551
Study 20970380 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate with whole brain radiotherapy
Number of subjects: 551
Study 20970380 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate without whole brain radiotherapy
Number of subjects: 551
Study 18519285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate care at a community hospital (n=72)
Number of subjects: 142
Study 18519285 — intervention group
Group type: COMPARATOR
Intervention: General hospital care (n=70)
Number of subjects: 142
Study 18519285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate care at a community hospital
Number of subjects: 142
Study 16030104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of selenium and vitamin E supplementation for 3 to 6 weeks before prostatectomy
Number of subjects: 48
Study 16030104 — intervention group
Group type: COMPARATOR
Intervention: Selenium supplementation
Number of subjects: 48
Study 16030104 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E supplementation
Number of subjects: 48
Study 16030104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12161049 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 46
Study 12161049 — intervention group
Group type: COMPARATOR
Intervention: Transdermal hormonal replacement therapy system
Number of subjects: 46
Study 12349828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad(GV)CFTR.10 administered to airways of individuals with cystic fibrosis (3 x 10(7) to 2 x 10(10) particle units)
Number of subjects: 0
Study 12349828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad(GV)VEGF121.10 administered to myocardium of individuals with coronary artery disease (4 x 10(8) to 4 x 10(10) particle units)
Number of subjects: 0
Study 12349828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad(GV)VEGF121.10 administered to lower extremity muscles of individuals with peripheral vascular disease (4 x 10(8) to 4 x 10(9.5) particle units)
Number of subjects: 0
Study 12349828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad(GV)CD.10 administered to skin of normal individuals (7 x 10(7) to 7 x 10(9) particle units)
Number of subjects: 0
Study 12349828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad(GV)CD.10 administered to airways of normal individuals (7 x 10(8) to 7 x 10(10) particle units)
Number of subjects: 0
Study 12349828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad(GV)CD.10 administered to liver metastasis of individuals with colon carcinoma (4 x 10(8) to 4 x 10(9) particle units)
Number of subjects: 0
Study 12349828 — intervention group
Group type: COMPARATOR
Intervention: Control individuals who had chest surgery and bronchoscopy, but no vector administration
Number of subjects: 0
Study 9790340 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy and retroperitoneal soft‐tissue clearance
Number of subjects: 81
Study 9790340 — intervention group
Group type: COMPARATOR
Intervention: Standard lymphadenectomy
Number of subjects: 81
Study 9790340 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Number of subjects: 81
Study 7500479 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 0
Study 7500479 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study 7500479 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance
Number of subjects: 0
Study 2136974 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaritide (0.03, 0.06, 0.075, and 0.100 microgram/kg/min)
Number of subjects: 28
Study 2136974 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaritide (all doses except the highest 0.300 microgram/kg/min)
Number of subjects: 28
Study 2136974 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaritide (0.060, 0.075, and 0.100 microgram/kg/min)
Number of subjects: 28
Study 2136974 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaritide (0.300 microgram/kg/min)
Number of subjects: 28
Study 2136974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 350491 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg bufexamac
Number of subjects: 40
Study 350491 — intervention group
Group type: COMPARATOR
Intervention: 40 mg triamcinolone acetonide
Number of subjects: 40
Study 350491 — intervention group
Group type: EXPERIMENTAL
Intervention: bufexamac
Number of subjects: 40
Study 350491 — intervention group
Group type: COMPARATOR
Intervention: triamcinolone acetonide
Number of subjects: 40
Study 350491 — intervention group
Group type: EXPERIMENTAL
Intervention: bufexamac and triamcinolone acetonide
Number of subjects: 40
Study 6981349 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion (when platelet count fell below 20,000 per mm3)
Number of subjects: 56
Study 6981349 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic platelet transfusion (only when significant bleeding occurred)
Number of subjects: 56
Study 29436942 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐mm‐long implants
Number of subjects: 36
Study 29436942 — intervention group
Group type: COMPARATOR
Intervention: Normal‐length implants (10 mm)
Number of subjects: 36
Study 26902546 — intervention group
Group type: EXPERIMENTAL
Intervention: DTwP vaccine first
Number of subjects: 130
Study 26902546 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine first
Number of subjects: 130
Study 24314586 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil based lipid emulsion (SmofLipid®)
Number of subjects: 80
Study 24314586 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil based lipid emulsion (Intralipid®)
Number of subjects: 80
Study 23136276 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated community case management (CMDs treating malaria and pneumonia)
Number of subjects: 1095
Study 23136276 — intervention group
Group type: COMPARATOR
Intervention: Home-based management (CMDs treating only malaria)
Number of subjects: 1095
Study 19787787 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 90
Study 19787787 — intervention group
Group type: COMPARATOR
Intervention: Clamp-and-tie technique
Number of subjects: 90
Study 18337284 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1500 mg QD (or 750 mg if bodyweight ≤30 kg)
Number of subjects: 353
Study 18337284 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 500 mg BID (or 250 mg if bodyweight ≤20 kg)
Number of subjects: 353
Study 16333048 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12846450 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human leptin (rL) 10 mg once daily
Number of subjects: 30
Study 12846450 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human leptin (rL) 10 mg twice daily
Number of subjects: 30
Study 12846450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9869578 — intervention group
Group type: COMPARATOR
Intervention: Sporanox (reference)
Number of subjects: 18
Study 9869578 — intervention group
Group type: EXPERIMENTAL
Intervention: Traconal (test)
Number of subjects: 18
Study 9869578 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited-sampling strategy models based on three sampling times
Number of subjects: 18
Study 9869578 — intervention group
Group type: COMPARATOR
Intervention: Three-point models developed for the reference formulation
Number of subjects: 18
Study 8877306 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic physiotherapeutic training
Number of subjects: 56
Study 8877306 — intervention group
Group type: COMPARATOR
Intervention: Static physiotherapeutic training
Number of subjects: 56
Study 1888817 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 202
Study 1888817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 6130195 — intervention group
Group type: EXPERIMENTAL
Intervention: Flubendazole 750 mg intramuscularly once a week for 5 doses
Number of subjects: 19
Study 6130195 — intervention group
Group type: COMPARATOR
Intervention: Diethylcarbamazine (DEC) 100 mg twice daily for 14 days
Number of subjects: 19
Study 30514114 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (36 sessions over 12 weeks, 45 minutes each session)
Number of subjects: 20
Study 30514114 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 20
Study 29917064 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 25 mg once daily
Number of subjects: 219
Study 29917064 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 75 mg once daily
Number of subjects: 219
Study 29917064 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 150 mg once daily
Number of subjects: 219
Study 29917064 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib 75 mg twice daily
Number of subjects: 219
Study 29917064 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined peficitinib group (>=75 mg o.d.)
Number of subjects: 219
Study 29917064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 27162098 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tACS at 1 mA peak-to-peak
Number of subjects: 0
Study 27162098 — intervention group
Group type: COMPARATOR
Intervention: Sham tACS (Control)
Number of subjects: 0
Study 24201090 — intervention group
Group type: EXPERIMENTAL
Intervention: Melbourne Infant Feeding, Activity and Nutrition Trial (InFANT) Program
Number of subjects: 542
Study 22980173 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of alprazolam
Number of subjects: 60
Study 22980173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19825218 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney beans
Number of subjects: 0
Study 19825218 — intervention group
Group type: EXPERIMENTAL
Intervention: Groundnuts
Number of subjects: 0
Study 19825218 — intervention group
Group type: EXPERIMENTAL
Intervention: Legumes (general)
Number of subjects: 0
Study 19014841 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course antibiotic therapy (7-14 days)
Number of subjects: 4
Study 19014841 — intervention group
Group type: COMPARATOR
Intervention: Long-course antibiotic therapy (14-42 days)
Number of subjects: 4
Study 16149276 — intervention group
Group type: EXPERIMENTAL
Intervention: Early diagnostic laparoscopy
Number of subjects: 110
Study 16149276 — intervention group
Group type: COMPARATOR
Intervention: Conventional diagnostic methods
Number of subjects: 110
Study 11812272 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) formulation of ipratropium bromide
Number of subjects: 39
Study 11812272 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry powder inhaler (DPI) formulation of ipratropium bromide
Number of subjects: 39
Study 11812272 — intervention group
Group type: COMPARATOR
Intervention: Both MDI and DPI
Number of subjects: 39
Study 11812272 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI
Number of subjects: 39
Study 10473326 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Assessment of Personality (SAP)
Number of subjects: 90
Study 10473326 — intervention group
Group type: COMPARATOR
Intervention: International Personality Disorder Examination (IPDE)
Number of subjects: 90
Study 8539604 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustically modified speech training with listening exercises and computer games for 4 weeks
Number of subjects: 0
Study 1897766 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL of 0.25% bupivacaine with epinephrine injected intrapleurally postoperatively
Number of subjects: 40
Study 1897766 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of 0.5% bupivacaine with epinephrine
Number of subjects: 40
Study 6183089 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandoglobulin
Number of subjects: 14
Study 6183089 — intervention group
Group type: COMPARATOR
Intervention: Gamma‐Venin
Number of subjects: 14
Study 29781941 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-kg kettlebell snatches
Number of subjects: 10
Study 29781941 — intervention group
Group type: COMPARATOR
Intervention: Graded-exercise test on a rowing ergometer
Number of subjects: 10
Study 30563273 — intervention group
Group type: EXPERIMENTAL
Intervention: two servings of protein (77.2 g, 586 kcal)
Number of subjects: 4
Study 30563273 — intervention group
Group type: EXPERIMENTAL
Intervention: two servings of carbohydrate (126.8 g, 582 kcal)
Number of subjects: 4
Study 30563273 — intervention group
Group type: EXPERIMENTAL
Intervention: one serving of protein (38.6 g, 293 kcal)
Number of subjects: 4
Study 30563273 — intervention group
Group type: EXPERIMENTAL
Intervention: one serving of carbohydrate (63.4 g, 291 kcal)
Number of subjects: 4
Study 30563273 — intervention group
Group type: COMPARATOR
Intervention: non-supplemented soldiers
Number of subjects: 4
Study 27797709 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (2 × 28 g/d)
Number of subjects: 42
Study 27797709 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium caseinate (2 × 28 g/d)
Number of subjects: 42
Study 27797709 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (control)
Number of subjects: 42
Study 23892826 — intervention group
Group type: EXPERIMENTAL
Intervention: Programs led by trained American Indian community members
Number of subjects: 0
Study 23892826 — intervention group
Group type: EXPERIMENTAL
Intervention: Free pharmacotherapy, including nicotine replacement therapy (NRT)
Number of subjects: 0
Study 23892826 — intervention group
Group type: EXPERIMENTAL
Intervention: Nominal incentives, e.g., gift cards for groceries
Number of subjects: 0
Study 23892826 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally specific program components
Number of subjects: 0
Study 23892826 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical verification of smoking abstinence
Number of subjects: 0
Study 23892826 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment or delayed treatment control groups
Number of subjects: 0
Study 23209576 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on ethyl-EPA supplementation
Number of subjects: 25
Study 23209576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 20843217 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of psychosocial skills training, family psycho-education and customary pharmacotherapy
Number of subjects: 83
Study 20843217 — intervention group
Group type: COMPARATOR
Intervention: Customary treatment alone
Number of subjects: 83
Study 18434045 — intervention group
Group type: EXPERIMENTAL
Intervention: LST+SFP 10-14
Number of subjects: 1677
Study 18434045 — intervention group
Group type: EXPERIMENTAL
Intervention: LST-alone
Number of subjects: 1677
Study 18434045 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1677
Study 18434045 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-risk subsample (LST+SFP 10-14 or LST-alone)
Number of subjects: 1677
Study 16435637 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive verbal presentation (EG)
Number of subjects: 60
Study 16435637 — intervention group
Group type: COMPARATOR
Intervention: Neutral explanation (CG)
Number of subjects: 60
Study 12811473 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk containing 1.8 g of non‐esterified pure plant sterols/d
Number of subjects: 16
Study 12811473 — intervention group
Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 16
Study 10509766 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncooked cornstarch (0.46 g available CHO/kg body weight)
Number of subjects: 16
Study 10509766 — intervention group
Group type: EXPERIMENTAL
Intervention: White bread (0.46 g available CHO/kg body weight)
Number of subjects: 16
Study 10509766 — intervention group
Group type: COMPARATOR
Intervention: Starch-free placebo ('normal' food regimen)
Number of subjects: 16
Study 8941515 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycogen (LG) trial
Number of subjects: 7
Study 8941515 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycogen (HG) trial
Number of subjects: 7
Study 1718348 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intra-arterial chemotherapy with vincristine and bleomycin for 12 days
Number of subjects: 222
Study 1718348 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intra-arterial chemotherapy
Number of subjects: 222
Study 1718348 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 222
Study 7039757 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone elastomer intravenous cannula (Visis)
Number of subjects: 0
Study 7039757 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene cannula (Cathlon)
Number of subjects: 0
Study 28006989 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Management Implementation Intentions training (GMTii)
Number of subjects: 30
Study 28006989 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 30
Study 30256751 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB/Arg/Gln (1.2 g HMB, 7 g L‐Arg, and 7 g L‐Gln)
Number of subjects: 61
Study 30256751 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isocaloric juice)
Number of subjects: 61
Study 30256751 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB/Arg/Gln
Number of subjects: 61
Study 25417170 — intervention group
Group type: EXPERIMENTAL
Intervention: Training + LLLT Group (TLG)
Number of subjects: 30
Study 25417170 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 30
Study 25417170 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study 23651717 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based rehabilitation (12 outpatient visits over six weeks including strength and endurance exercises, education, and self-management)
Number of subjects: 80
Study 23651717 — intervention group
Group type: COMPARATOR
Intervention: Individual, supervised home-training
Number of subjects: 80
Study 20959720 — intervention group
Group type: EXPERIMENTAL
Intervention: UAG 200 μg
Number of subjects: 8
Study 20959720 — intervention group
Group type: EXPERIMENTAL
Intervention: UAG 100 μg + AG 100 μg (Comb)
Number of subjects: 8
Study 20959720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 19536041 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-9 vaccination
Number of subjects: 2342
Study 19536041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2342
Study 19536041 — intervention group
Group type: COMPARATOR
Intervention: Younger siblings (non-PCV-9 vaccinated)
Number of subjects: 2342
Study 16451435 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating ultrasonic insert
Number of subjects: 32
Study 16451435 — intervention group
Group type: COMPARATOR
Intervention: Standard universal insert
Number of subjects: 32
Study 15626267 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion
Number of subjects: 4992
Study 15626267 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or untreated)
Number of subjects: 4992
Study 11291357 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg twice a day)
Number of subjects: 77
Study 11291357 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg four times a day)
Number of subjects: 77
Study 11291357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 9211127 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone (0.8 mg i.v. bolus, followed by infusion of 1.6 mg/h for 120')
Number of subjects: 7
Study 9211127 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-MSH (2.5 mg i.v. bolus)
Number of subjects: 7
Study 9211127 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone + alpha-MSH (2.5 mg i.v. 15' after commencement of the naloxone infusion)
Number of subjects: 7
Study 9211127 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH (100 micrograms i.v. at time 0)
Number of subjects: 7
Study 9211127 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH + naloxone (100 micrograms i.v. 15' after commencement of the naloxone infusion)
Number of subjects: 7
Study 9211127 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH + alpha-MSH (100 micrograms i.v. 15' after commencement of the naloxone infusion)
Number of subjects: 7
Study 9211127 — intervention group
Group type: COMPARATOR
Intervention: placebo (150 nmol/l NaCl solution)
Number of subjects: 7
Study 9211127 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH alone (100 micrograms at time 0)
Number of subjects: 7
Study 9211127 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH + naloxone
Number of subjects: 7
Study 9211127 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH + alpha-MSH
Number of subjects: 7
Study 9211127 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study 7699834 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 at a dose of 5 mg/kg
Number of subjects: 16